Edward Jordan
Corporate Officer/Principal bei XSPRAY PHARMA AB
Vermögen: - $ am 31.03.2024
Profil
Edward P.
Jordan is currently the Chief Commercial Officer at Xspray Pharma AB since 2023.
Prior to this, he was the Chief Commercial Officer at Humanigen, Inc. from 2020 to 2023 and Senior Vice President at DBV Technologies, Inc. from 2016 to 2020.
He also held a senior leadership position at AMAG Pharmaceuticals, Inc. Mr. Jordan has an undergraduate degree from the University of Rhode Island and an MBA from Southern New Hampshire University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
HUMANIGEN INC
0,01% | 11.04.2023 | 12 500 ( 0,01% ) | 0 $ | 31.03.2024 |
Aktive Positionen von Edward Jordan
| Unternehmen | Position | Beginn |
|---|---|---|
| XSPRAY PHARMA AB | Corporate Officer/Principal | 15.09.2023 |
Ehemalige bekannte Positionen von Edward Jordan
| Unternehmen | Position | Ende |
|---|---|---|
| HUMANIGEN, INC. | Corporate Officer/Principal | 14.09.2023 |
DBV Technologies, Inc.
 DBV Technologies, Inc. Medical/Nursing ServicesHealth Services Part of DBV Technologies SA, DBV Technologies, Inc. provides medical care services. The private company is based in New York, NY. | Corporate Officer/Principal | 24.08.2020 |
| AMAG PHARMACEUTICALS, INC. | Sales & Marketing | - |
Ausbildung von Edward Jordan
| University of Rhode Island | Undergraduate Degree |
| Southern New Hampshire University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| HUMANIGEN, INC. | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| Private Unternehmen | 2 |
|---|---|
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
DBV Technologies, Inc.
DBV Technologies, Inc. Medical/Nursing ServicesHealth Services Part of DBV Technologies SA, DBV Technologies, Inc. provides medical care services. The private company is based in New York, NY. | Health Services |
